LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Envista Holdings Corp

Geschlossen

BrancheGesundheitswesen

28.97 0.84

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

28.89

Max

29.06

Schlüsselkennzahlen

By Trading Economics

Einkommen

63M

33M

Verkäufe

81M

751M

KGV

Branchendurchschnitt

104.857

121.746

EPS

0.38

Gewinnspanne

4.383

Angestellte

12,300

EBITDA

-23M

73M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

-1.62% downside

Dividenden

By Dow Jones

Nächstes Ergebnis

30. Apr. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1B

4.9B

Vorheriger Eröffnungskurs

28.13

Vorheriger Schlusskurs

28.97

Nachrichtenstimmung

By Acuity

50%

50%

127 / 351 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Envista Holdings Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Feb. 2026, 23:21 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15. Feb. 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15. Feb. 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15. Feb. 2026, 23:06 UTC

Ergebnisse

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15. Feb. 2026, 23:04 UTC

Ergebnisse

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15. Feb. 2026, 23:04 UTC

Ergebnisse

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15. Feb. 2026, 23:01 UTC

Ergebnisse

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15. Feb. 2026, 23:01 UTC

Ergebnisse

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15. Feb. 2026, 22:53 UTC

Akquisitionen, Fusionen, Übernahmen

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15. Feb. 2026, 22:53 UTC

Akquisitionen, Fusionen, Übernahmen

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15. Feb. 2026, 22:52 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Shareholders to Receive A$5.20/Share in Cash

15. Feb. 2026, 22:52 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15. Feb. 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO Tania Archibald Speaking on a Call With Media

15. Feb. 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15. Feb. 2026, 22:16 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15. Feb. 2026, 22:14 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15. Feb. 2026, 22:14 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15. Feb. 2026, 20:48 UTC

Ergebnisse

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15. Feb. 2026, 20:47 UTC

Ergebnisse

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15. Feb. 2026, 20:46 UTC

Ergebnisse

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15. Feb. 2026, 20:45 UTC

Ergebnisse

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15. Feb. 2026, 20:44 UTC

Ergebnisse

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15. Feb. 2026, 20:44 UTC

Ergebnisse

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15. Feb. 2026, 20:43 UTC

Ergebnisse

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15. Feb. 2026, 20:42 UTC

Ergebnisse

BlueScope Net Debt A$2.2 Million at Dec. 31

15. Feb. 2026, 20:42 UTC

Ergebnisse

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15. Feb. 2026, 20:41 UTC

Ergebnisse

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15. Feb. 2026, 20:40 UTC

Ergebnisse

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15. Feb. 2026, 20:40 UTC

Ergebnisse

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15. Feb. 2026, 20:39 UTC

Ergebnisse

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Peer-Vergleich

Kursveränderung

Envista Holdings Corp Prognose

Kursziel

By TipRanks

-1.62% Nachteil

12-Monats-Prognose

Durchschnitt 28.5 USD  -1.62%

Hoch 35 USD

Tief 19 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Envista Holdings Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

14 ratings

7

Buy

7

Halten

0

Sell

Technischer Score

By Trading Central

15.98 / N/AUnterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

127 / 351 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Envista Holdings Corp

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
help-icon Live chat